|
Molecular testing during AML treatment for early prediction of clinical response. |
|
|
No Relationships to Disclose |
|
|
Research Funding - Cellective; Novartis |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Gilead Sciences; incyte; Kite, a Gilead company; Millennium (I); novartis; onyx (I); pfizer; pharmacyclics; Sanofi; Seagen; Teva |
Speakers' Bureau - Celgene; Celgene (I); Gilead Sciences; incyte; Millennium (I); Seagen |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
Christopher Simon Hourigan |
No Relationships to Disclose |